Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

109 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Anemia and Iron Deficiency in Outpatients with Inflammatory Bowel Disease: Ubiquitous Yet Suboptimally Managed.
Loveikyte R, Boer M, van der Meulen CN, Ter Steege RWF, Tack G, Kuyvenhoven J, Jharap B, Vu MK, Vogelaar L, West RL, van der Marel S, Römkens TEH, Mujagic Z, Hoentjen F, van Bodegraven AA, van Schaik FDM, de Vries AC, Dijkstra G, van der Meulen-de Jong AE; Dutch Initiative on Crohn and Colitis (ICC). Loveikyte R, et al. J Clin Med. 2022 Nov 19;11(22):6843. doi: 10.3390/jcm11226843. J Clin Med. 2022. PMID: 36431320 Free PMC article.
Effectiveness and safety of tofacitinib for ulcerative colitis: two-year results of the ICC Registry.
Straatmijer T, van Schaik FDM, Bodelier AGL, Visschedijk M, de Vries AC, Ponsioen CY, Pierik M, van Bodegraven AA, West RL, de Boer NKH, Srivastava N, Romkens TEH, Hoekstra J, Oldenburg B, Dijkstra G, van der Woude JC, Löwenberg M, Mujagic Z, Biemans VBC, van der Meulen-de Jong AE, Duijvestein M. Straatmijer T, et al. Aliment Pharmacol Ther. 2023 Jan;57(1):117-126. doi: 10.1111/apt.17248. Epub 2022 Oct 25. Aliment Pharmacol Ther. 2023. PMID: 36282200 Free PMC article.
Increased versus conventional adalimumab dose interval for patients with Crohn's disease in stable remission (LADI): a pragmatic, open-label, non-inferiority, randomised controlled trial.
van Linschoten RCA, Jansen FM, Pauwels RWM, Smits LJT, Atsma F, Kievit W, de Jong DJ, de Vries AC, Boekema PJ, West RL, Bodelier AGL, Gisbertz IAM, Wolfhagen FHJ, Römkens TEH, Lutgens MWMD, van Bodegraven AA, Oldenburg B, Pierik MJ, Russel MGVM, de Boer NK, Mallant-Hent RC, Ter Borg PCJ, van der Meulen-de Jong AE, Jansen JM, Jansen SV, Tan ACITL, van der Woude CJ, Hoentjen F; LADI study group and the Dutch Initiative on Crohn and Colitis. van Linschoten RCA, et al. Lancet Gastroenterol Hepatol. 2023 Apr;8(4):343-355. doi: 10.1016/S2468-1253(22)00434-4. Epub 2023 Jan 31. Lancet Gastroenterol Hepatol. 2023. PMID: 36736339 Clinical Trial.
Prognostic Value of the Modified Rutgeerts Score for Long-Term Outcomes After Primary Ileocecal Resection in Crohn's Disease.
Bak MTJ, Ten Bokkel Huinink S, Erler NS, Bodelier AGL, Dijkstra G, Romberg-Camps M, de Boer NKH, Hoentjen F, Stassen LPS, van der Meulen-de Jong AE, West RL, van Ruler O, van der Woude CJ, de Vries AC; Dutch Initiative on Crohn and Colitis (ICC). Bak MTJ, et al. Among authors: van der meulen de jong ae. Am J Gastroenterol. 2024 Feb 1;119(2):306-312. doi: 10.14309/ajg.0000000000002509. Epub 2023 Nov 1. Am J Gastroenterol. 2024. PMID: 37737675 Free PMC article.
Smoking and colorectal neoplasia in patients with inflammatory bowel disease: Dose-effect relationship.
Wijnands AM, Elias SG, Dekker E, Fidder HH, Hoentjen F, Ten Hove JR, Maljaars PWJ, van der Meulen-de Jong AE, Mooiweer E, Ouwehand RJ, Penning de Vries BBL, Ponsioen CY, van Schaik FDM, Oldenburg B; Dutch Initiative on Crohn's and Colitis (ICC). Wijnands AM, et al. Among authors: van der meulen de jong ae. United European Gastroenterol J. 2023 Sep;11(7):612-620. doi: 10.1002/ueg2.12426. Epub 2023 Jul 28. United European Gastroenterol J. 2023. PMID: 37505117 Free PMC article.
Frailty Screening is Associated with Hospitalization and Decline in Quality of Life and Functional Status in Older Patients with Inflammatory Bowel Disease.
Asscher VER, Rodriguez Gírondo M, Fens J, Waars SN, Stuyt RJL, Baven-Pronk AMC, Srivastava N, Jacobs RJ, Haans JJL, Meijer LJ, Klijnsma-Slagboom JD, Duin MH, Peters MER, Lee-Kong FVYL, Provoost NE, Tijdeman F, van Dijk KT, Wieland MWM, Verstegen MGM, van der Meijs ME, Maan ADI, van Deudekom FJ, van der Meulen-de Jong AE, Mooijaart SP, Maljaars PWJ. Asscher VER, et al. Among authors: van der meulen de jong ae. J Crohns Colitis. 2024 Apr 23;18(4):516-524. doi: 10.1093/ecco-jcc/jjad175. J Crohns Colitis. 2024. PMID: 37870484 Free PMC article.
Cost-Effectiveness Analysis of Increased Adalimumab Dose Intervals in Crohn's Disease Patients in Stable Remission: The Randomized Controlled LADI Trial.
Jansen FM, van Linschoten RCA, Kievit W, Smits LJT, Pauwels RWM, de Jong DJ, de Vries AC, Boekema PJ, West RL, Bodelier AGL, Gisbertz IAM, Wolfhagen FHJ, Römkens TEH, Lutgens MWMD, van Bodegraven AA, Oldenburg B, Pierik MJ, Russel MGVM, de Boer NK, Mallant-Hent RC, Ter Borg PCJ, van der Meulen-de Jong AE, Jansen JM, Jansen SV, Tan ACITL, Hoentjen F, van der Woude CJ; LADI study group. Jansen FM, et al. J Crohns Colitis. 2023 Nov 24;17(11):1771-1780. doi: 10.1093/ecco-jcc/jjad101. J Crohns Colitis. 2023. PMID: 37310877 Free PMC article. Clinical Trial.
Patient preferences in treatment options of ulcerative colitis: a discrete choice experiment.
Straatmijer T, van den Akker-van Marle ME, Ponsioen CY, van der Horst D, Scherpenzeel MP, Duijvestein M, van der Meulen-de Jong AE. Straatmijer T, et al. Among authors: van der meulen de jong ae. Scand J Gastroenterol. 2024 Mar;59(3):288-295. doi: 10.1080/00365521.2023.2286191. Epub 2023 Dec 2. Scand J Gastroenterol. 2024. PMID: 38042982
Immunomodulatory effects of mesenchymal stromal cells in Crohn's disease.
Molendijk I, Duijvestein M, van der Meulen-de Jong AE, van Deen WK, Swets M, Hommes DW, Verspaget HW. Molendijk I, et al. J Allergy (Cairo). 2012;2012:187408. doi: 10.1155/2012/187408. Epub 2012 Sep 20. J Allergy (Cairo). 2012. PMID: 23049573 Free PMC article.
109 results